Greenwich LifeSciences (NASDAQ:GLSI) Announces Earnings Results, Beats Estimates By $0.06 EPS

Greenwich LifeSciences (NASDAQ:GLSI) announced its quarterly earnings results on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.06, FiscalAI reports.

Greenwich LifeSciences Stock Up 0.3%

Shares of GLSI traded up $0.05 during trading hours on Tuesday, reaching $15.55. 107,206 shares of the company traded hands, compared to its average volume of 237,813. The company’s fifty day moving average price is $19.16 and its two-hundred day moving average price is $23.53. The company has a market capitalization of $228.27 million, a price-to-earnings ratio of -9.90 and a beta of 1.46. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10.

Wall Street Analyst Weigh In

GLSI has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. HC Wainwright boosted their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen downgraded Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Greenwich LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $57.00.

Insider Transactions at Greenwich LifeSciences

In related news, CEO Snehal Patel purchased 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The stock was bought at an average cost of $13.14 per share, with a total value of $32,850.00. Following the completion of the purchase, the chief executive officer directly owned 5,606,602 shares in the company, valued at approximately $73,670,750.28. This represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 5,800 shares of company stock valued at $76,618 over the last ninety days. 51.47% of the stock is owned by corporate insiders.

Institutional Trading of Greenwich LifeSciences

Large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new position in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $509,000. Man Group plc purchased a new position in shares of Greenwich LifeSciences in the 4th quarter valued at approximately $590,000. Strs Ohio bought a new stake in shares of Greenwich LifeSciences during the first quarter valued at approximately $177,000. State Street Corp boosted its position in shares of Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after purchasing an additional 13,179 shares in the last quarter. 4.16% of the stock is owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.